Biotech Most Volatile: MannKind Corporation (NASDAQ:MNKD), Inovio Pharmaceuticals (NYSEMKT:INO), Galena Biopharma (NASDAQ:GALE), Geron Corporation (NASDAQ:GERN)

MannKind Corporation (NASDAQ:MNKD) on Feb. 18 reported financial results for the fourth quarter and full year ended December 31, 2013. The net loss applicable to common stockholders for fiscal year 2013 was $(191.5) million, or $(0.64) per share based on 299.6 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $(169.4) million, or $(0.94) per share based on 180.9 … Continue reading Biotech Most Volatile: MannKind Corporation (NASDAQ:MNKD), Inovio Pharmaceuticals (NYSEMKT:INO), Galena Biopharma (NASDAQ:GALE), Geron Corporation (NASDAQ:GERN)

Biotech Losers: Geron Corporation (NASDAQ:GERN), OXiGENE Inc (NASDAQ:OXGN), Opexa Therapeutics Inc (NASDAQ:OPXA), 22nd Century Group Inc (NYSEMKT:XXII)

Brower Piven, A Professional Corporation on Mar. 18 announced that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Geron Corporation (NASDAQ:GERN) securities during the period between June 16, 2013 and March 11, 2014, inclusive (the “Class Period”). Geron Corporation (NASDAQ:GERN) stock performance was -8.06% in last session and finished … Continue reading Biotech Losers: Geron Corporation (NASDAQ:GERN), OXiGENE Inc (NASDAQ:OXGN), Opexa Therapeutics Inc (NASDAQ:OPXA), 22nd Century Group Inc (NYSEMKT:XXII)

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Geron Corporation (NASDAQ:GERN) securities during the period between June 16, 2013 and March 11, 2014, inclusive (the “Class Period”). Geron Corporation (NASDAQ:GERN) stock performance was 39.33% in last session and finished the day at … Continue reading Biotech Gainers: Geron Corporation (NASDAQ:GERN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Opexa Therapeutics Inc. (NASDAQ:OPXA)

The iShares Biotechnology Indexhas fallen 2.46% in the last month of trading, and biotech stalwarts Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD ) are both down over 8%. What’s most surprising is that Celgene and Gilead are expected to have strong years in terms of earnings and the development of their respective clinical pipelines. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 0.53% in last session and … Continue reading Biotech Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Inovio Pharmaceuticals Inc (NYSEMKT:INO), Geron Corporation (NASDAQ:GERN)

Geron Corp. (NASDAQ:GERN) stock had its “positive” rating reiterated by equities research analysts at Wells Fargo & Co. in a research note issued to investors on Thursday, American Banking News.com reports.Geron Corporation (NASDAQ:GERN) stock performance was -2.73% in last session and finished the day at $1.78. Traded volume was 7,214,860 million shares in the last session and the average volume of the stock remained 5.57 … Continue reading Biotech Volatile Stocks: Geron Corporation (NASDAQ:GERN), Novavax (NASDAQ:NVAX), Aegerion Pharmaceuticals (NASDAQ:AEGR), CytRx Corporation (NASDAQ:CYTR)

A US federal court yesterday invalidated Pfizer Inc.’s (NYSE:PFE) key patent covering its anti-inflammatory pill Celebrex. The patent, which was set to lapse in December 2015, would have given Pfizer an 18-month extension from the expiry of the patent for the major ingredient in the drug, celecoxib. Pfizer Inc. (NYSE:PFE) stock performance was -2.69% in last session and finished the day at $31.12. Traded volume … Continue reading Biotech Active Stocks: Pfizer Inc. (NYSE:PFE), Geron Corporation (NASDAQ:GERN), Cell Therapeutics (NASDAQ:CTIC), Chelsea Therapeutics International (NASDAQ:CHTP)